These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38629497)

  • 41. Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study.
    Passeron T; Reinhardt M; Ehst B; Weiss J; Sluzevich J; Sticherling M; Reygagne P; Wohlrab J; Hertl M; Fazel N; Muscianisi E; Fan H; Hampele I; Compagno N
    Br J Dermatol; 2024 Oct; 191(5):680-690. PubMed ID: 38735684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study.
    Silverberg JI; Pinter A; Alavi A; Lynde C; Bouaziz JD; Wollenberg A; Murrell DF; Alpizar S; Laquer V; Chaouche K; Ahmad F; Armstrong JM; Piketty C
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1562-1568. PubMed ID: 33711179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating meaningful change thresholds for Skin Pain-Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis.
    Stander S; Kim BS; Guillemin I; Rhoten S; Wratten S; Brookes E; O'Malley JT; Bansal A; Msihid J; Thomas R; Bahloul D
    J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1401-1409. PubMed ID: 38329222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation.
    Ständer S; Zeidler C; Pereira M; Szepietowski JC; McLeod L; Qin S; Williams N; Sciascia T; Augustin M
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):573-581. PubMed ID: 34908192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.
    Matterne U; Böhmer MM; Weisshaar E; Jupiter A; Carter B; Apfelbacher CJ
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012167. PubMed ID: 30666626
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A real-world observational study of dupilumab treatment in adult patients with prurigo nodularis.
    Zhang Z; Li S; Wang Y; Zhao J
    An Bras Dermatol; 2023; 98(4):440-448. PubMed ID: 36966024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful Treatment of Prurigo Nodularis by Dupilumab: Report of 24 Patients.
    Gao Z; Dou Y; Zhao P; Wang CJ; Zhang J
    Dermatology; 2023; 239(4):658-663. PubMed ID: 37011607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
    Merola JF; Chiou AS; During E; Costanzo A; Foley P; Alfalasi A; Gogate S; Pinter A; Dodiuk-Gad R; Simon D; Tauber M; Weller R; Pereyra-Rodriguez JJ; Ardeleanu M; Wu J; Ozturk ZE
    Br J Dermatol; 2023 Nov; 189(6):685-694. PubMed ID: 37562034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial.
    Kabashima K; Matsumura T; Hayakawa Y; Kawashima M;
    J Dermatolog Treat; 2023 Dec; 34(1):2177096. PubMed ID: 36779675
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.
    Murota H; Arima K; Yoshida T; Fujita H
    J Dermatol; 2024 Feb; 51(2):223-233. PubMed ID: 38066728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interventions for chronic pruritus of unknown origin.
    Andrade A; Kuah CY; Martin-Lopez JE; Chua S; Shpadaruk V; Sanclemente G; Franco JV
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD013128. PubMed ID: 31981369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
    von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
    J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.
    Serra-Baldrich E; Santamaría-Babí LF; Francisco Silvestre J
    Actas Dermosifiliogr; 2022; 113(7):674-684. PubMed ID: 35842249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents.
    Sidbury R; Alpizar S; Laquer V; Dhawan S; Abramovits W; Loprete L; Krishnaswamy JK; Ahmad F; Jabbar-Lopez Z; Piketty C
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):631-642. PubMed ID: 35088348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.
    Ma F; Gharaee-Kermani M; Tsoi LC; Plazyo O; Chaskar P; Harms P; Patrick MT; Xing X; Hile G; Piketty C; Lazzari A; Van Delm W; Maverakis E; Nakamura M; Modlin RL; Kahlenberg JM; Billi AC; Julia V; Krishnaswamy JK; Gudjonsson JE
    J Allergy Clin Immunol; 2024 Jan; 153(1):146-160. PubMed ID: 37506977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.